More than 40% of American adults struggle with obesity, while over 37 million live with diabetes. Recent medical advances have brought attention to GLP-1 drugs as a breakthrough in treating these conditions.
GLP-1 medications work by mimicking a natural hormone that regulates blood sugar and appetite. These prescription medications help control blood sugar levels in diabetes patients and support weight management through multiple mechanisms in the body.
This article takes a look at how GLP-1 drugs work, their benefits, potential side effects, and who might be suitable candidates for this treatment option. Readers will learn about the different types of GLP-1 agonists available, their effectiveness, and important safety considerations to discuss with healthcare providers. Please note this article is not meant to be medical advice; you must consult a licensed healthcare provider to determine whether or not you may be an eligible candidate for any GLP-1 medications based on your individual health circumstances.
What are GLP-1 Agonists?
GLP-1 agonists, formally known as glucagon-like peptide-1 receptor agonists, represent a class of medications which help manage blood sugar levels and support weight loss [4]. These drugs function by copying the effects of GLP-1, a natural hormone released by the gastrointestinal tract after eating [5].
First approved by the FDA in 2005 [6], these medications have established themselves as valuable tools in medical treatment. They are available in two primary forms:
- Injectable medications (most common form)
- Oral tablets (newer option, specifically semaglutide)
The medical community recognizes these drugs under several names, including:
- Incretin mimetics
- GLP-1 receptor agonists
- GLP-1 analogs
While initially developed for type 2 diabetes management, their application has expanded. The FDA has now approved several GLP-1 agonists for weight management in people with obesity who don't have diabetes. These medications work alongside other treatment strategies, as they alone cannot fully address type 2 diabetes or obesity.
Semaglutide tablets work by stimulating GLP-1 receptors to enhance insulin secretion, reduce glucagon release, and suppress appetite, helping to control blood sugar and promote weight loss, with studies showing that they are both safe and effective when taken as prescribed for type 2 diabetes or weight management.
These medications stand out for their ability to improve glycemic control while offering additional health advantages. Studies demonstrate their superiority over other antihyperglycemic drugs in several areas:
- Glycemic effectiveness
- Weight reduction
- Blood pressure improvement
- Cardiovascular protection
Importantly, when used alone, these benefits come without a significant risk of hypoglycemia. Healthcare providers typically prescribe GLP-1 agonists when blood sugar levels cannot be effectively managed with standard tablets [7].
How GLP-1 Agonists Work in the Body
The human body naturally produces GLP-1 hormone in the small intestine within minutes after eating [8]. GLP-1 agonist medications work by mimicking this natural hormone's actions, binding to specific receptors throughout the body [9].
Mechanism of Action of GLP-1 Agonists
These medications operate through multiple coordinated mechanisms in the body. When administered, GLP-1 agonists:
- Trigger insulin release from the pancreas in response to glucose
- Block glucagon secretion, preventing blood sugar increase
- Slow stomach emptying, affecting digestion rate
- Increase feelings of fullness through brain signaling
The medication binds to GLP-1 receptors found in various tissues, including pancreatic cells, gastric mucosa, kidney, lung, heart, and the hypothalamus [10]. This widespread distribution explains their diverse effects throughout the body.
Benefits of GLP-1 Agonists
The multi-targeted approach of GLP-1 agonists leads to several clinical advantages. These medications demonstrate significant improvements in blood glucose control while maintaining a low risk of hypoglycemia [11]. Studies show they can reduce HbA1c levels between 0.8% and 1.8% [12].
Beyond glucose management, GLP-1 agonists offer additional health benefits. Research indicates these medications can improve blood pressure levels and help manage lipid disorders. They also show promise in addressing fatty liver disease and may help slow the progression of diabetes-related kidney complications.
The medications' effect on the brain's appetite centers produces sustained weight loss in most patients, typically achieved within the first 3-6 months of treatment. Individual responses vary significantly, with weight loss ranging from minimal changes to reductions exceeding 15% of body weight.
Conditions Treated by GLP-1 Agonists
While initially developed for diabetes treatment, GLP-1 agonists now address multiple medical conditions. The FDA has officially approved these medications for two primary conditions:
- Type 2 Diabetes: As a primary or secondary treatment option when metformin alone isn't sufficient
- Obesity: For adults with a BMI of 30 or higher or those with a BMI of 25-29.9 with weight-related health conditions
Recent clinical studies have shown that GLP-1 agonists provide significant benefits for cardiovascular health. Research involving 67,769 participants demonstrated that these medications reduced major adverse cardiovascular events by 13% and all-cause death by 12% [13].
These medications also show promise in protecting kidney function. Studies indicate an 18% reduction in composite kidney outcomes and a 16% decrease in kidney failure risk. GLP-1 agonists can help slow disease progression for patients with chronic kidney disease by addressing multiple risk factors [14].
Research has identified additional conditions that may benefit from GLP-1 agonist treatment. Polycystic ovary syndrome (PCOS) patients have shown improvements in testosterone levels and body mass index when treated with these medications [15]. The medications have also demonstrated potential in treating nonalcoholic fatty liver disease (NAFLD), with studies showing improved liver function compared to other treatments.
Emerging research suggests possible applications for neurological conditions, including Parkinson's disease, where GLP-1 agonists may help improve motor function. These applications require additional research before becoming standard treatment options.
The best semaglutide for weight loss is typically the injectable form, as it has been shown to produce more significant and consistent results in reducing body weight compared to the oral version when combined with a healthy diet and regular exercise.
Healthcare providers typically prescribe these medications as part of a comprehensive treatment approach, often combining them with other therapies for optimal results.
Commonly Prescribed GLP-1 Agonists
Several pharmaceutical companies have developed effective GLP-1 agonist medications with unique characteristics and applications.
Top GLP-1 Agonist Medications on the Market
The current market leaders include:
- Ozempic® (semaglutide): A once-weekly injection that posted sales of USD 13.80 billion in 2023 [16]
- Mounjaro® (tirzepatide): Expected to generate annual sales of USD 33.40 billion by 2029
- Wegovy® (semaglutide): Specifically approved for weight management
- Rybelsus® (semaglutide): The first oral GLP-1 option
Comparing GLP-1 Options
Clinical trials have demonstrated varying degrees of effectiveness among these medications. Tirzepatide, available as Mounjaro® and Zepbound®, has shown results, helping participants achieve an average weight loss of 18% with 15mg weekly doses.
In terms of glycemic control, longer-acting GLP-1 medications have demonstrated superior results. Clinical comparisons show that daily or weekly formulations achieve significantly better blood sugar control compared to twice-daily options [17].
The administration methods and frequencies vary among medications:
- Once-weekly injections: Wegovy®, Ozempic®, Mounjaro®
- Once-daily oral: Rybelsus®
- Once-daily injections: Saxenda®, Victoza®
Recent developments have focused on improving patient convenience. The introduction of once-weekly formulations has significantly enhanced treatment adherence compared to medications requiring daily administration. Additionally, pharmaceutical companies continue developing new formulations, with expectations of one to two new GLP-1 launches annually starting in 2026 [18].
To get semaglutide at a lower cost, you can explore options like using manufacturer discount programs, checking for insurance coverage, or considering generic or pharmacy discount cards that may reduce out-of-pocket expenses.
Side Effects and Risks of GLP-1 Agonists
Understanding potential GLP-1 side effects and risks is crucial for patients considering GLP-1 agonist medications. While these drugs offer significant benefits, healthcare providers carefully monitor patients for adverse reactions.
Common Side Effects of GLP-1 Agonists
Most side effects associated with GLP-1 agonists affect the digestive system and typically improve as treatment continues [19]. The most frequently reported side effects include:
- Nausea and vomiting
- Diarrhea or constipation
- Headache
- Injection site reactions
- Abdominal pain
Studies indicate that gastrointestinal symptoms occur in up to 50% of patients, though these effects are usually mild to moderate and decrease over time [20].
Risks and Warnings of GLP-1 Agonists
The FDA actively monitors several serious risks associated with these medications. Recent studies have shown increased risks of specific conditions, including:
- Pancreatitis (9.09 times higher risk compared to alternative treatments)
- Bowel obstruction (4.22 times higher risk)
- Gastroparesis (3.67 times higher risk)
Healthcare providers must carefully screen patients for risk factors that could contraindicate GLP-1 agonist use. These medications are not recommended for individuals who:
- Have a history of medullary thyroid cancer
- Have experienced pancreatitis
- Are pregnant or breastfeeding
- Have certain types of kidney disease
The FDA has issued specific warnings about unapproved versions of these medications. Between 2023-2024, there were more than 392 adverse event reports with compounded semaglutide and 215 reports with compounded tirzepatide.
Mental health monitoring is also essential during treatment. Healthcare providers should watch for and advise patients to report any unusual changes in mood or behavior [21].
Who Should Consider GLP-1 Agonists?
Healthcare providers may evaluate several factors when determining if patients should consider GLP-1 agonist medications. These medications are particularly suitable for individuals whose diabetes isn't adequately controlled with traditional therapies, especially when their A1C remains higher than their target despite current treatment.
Patients who may benefit from GLP-1 agonists include those with:
- Type 2 diabetes when metformin alone isn't sufficient
- Obesity (BMI of 30 kg/m² or higher)
- Overweight (BMI 27 kg/m² or higher) with at least one weight-related health condition
- Cardiovascular disease requiring additional management
- Challenges achieving glycemic control with current treatments [22]
The selection process involves considering individual patient characteristics and health goals. Studies show that GLP-1 agonists are particularly effective when comorbidities are present, as they offer additional cardiovascular and gastrointestinal benefits that promote better overall health.
These medications may not be suitable for everyone. Healthcare providers will generally not prescribe GLP-1 agonists to patients who are pregnant, have severe gastrointestinal conditions like inflammatory bowel disease, or face an increased risk of certain thyroid cancers. Additionally, individuals with a history of pancreatitis, kidney failure, or gallbladder disease may need to explore alternative treatments. Please contact your licensed healthcare provider to discuss further details.
Patient preferences also play a crucial role in treatment decisions. Research indicates that factors such as dose frequency, device type, and needle size significantly influence patient satisfaction and adherence to treatment. Healthcare providers work closely with patients to select the most appropriate GLP-1 option based on individual needs, lifestyle factors, and treatment goals.
The decision to start GLP-1 agonist therapy should involve open discussion between patients and healthcare providers about treatment goals, potential benefits, and lifestyle modifications. Studies demonstrate that patient involvement in treatment decisions can significantly impact medication adherence and overall treatment success.
Final Thoughts
GLP-1 agonist medications represent a advancement in treating type 2 diabetes and obesity. These medications work through multiple mechanisms, helping patients manage blood sugar levels while supporting meaningful weight loss. Clinical studies demonstrate their effectiveness in reducing HbA1c levels, improving cardiovascular health, and protecting kidney function.
Healthcare providers carefully evaluate patient eligibility, considering medical history, current health status, and treatment goals. While these medications offer benefits, patients should understand their advantages and potential risks. Though typically manageable, side effects require careful monitoring and open communication with healthcare providers.
The evolution of GLP-1 agonists continues with new formulations and delivery methods, making treatment more convenient for patients. Success with these medications depends on their integration into a comprehensive treatment approach that includes appropriate lifestyle modifications and regular medical supervision.
Medical science recognizes GLP-1 agonists as valuable tools for managing chronic conditions, particularly when traditional treatments prove insufficient. Their demonstrated effectiveness and ongoing research and development position these medications as important options in modern medical treatment.
FAQ
What drugs are GLP-1 agonists?
The FDA has approved several GLP-1 agonist medications, including:
- Semaglutide (Ozempic, Wegovy, Rybelsus)
- Dulaglutide (Trulicity)
- Liraglutide (Victoza, Saxenda)
- Exenatide (Bydureon BCise, Byetta)
- Lixisenatide (Adlyxin)
These medications come in different forms, from daily to weekly injections and oral tablets. Tirzepatide (Mounjaro) represents a newer class called dual GLP-1/GIP receptor agonists.
Which GLP-1 is best for weight loss?
Clinical studies indicate that semaglutide and tirzepatide show the strongest results for weight loss. Research demonstrates that participants using semaglutide achieved an average 16% body weight reduction over 68 weeks, compared to 5.7% in the placebo group. Dulaglutide and liraglutide also demonstrate significant weight loss benefits, though somewhat less pronounced than semaglutide and tirzepatide.
The effectiveness of these medications varies among individuals. Factors affecting results include:
- Dosage and administration schedule
- Individual response to treatment
- Adherence to prescribed regimen
- Combination with lifestyle changes
Healthcare providers typically determine the most suitable option based on individual patient factors, including medical history and treatment goals.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
References
- Pharmaceutical Technology. How the GLP-1 receptor agonist market could hit $168bn by 2033. Pharmaceutical Technology. https://www.pharmaceutical-technology.com/sponsored/how-the-glp-1-receptor-agonist-market-could-hit-168bn-by-2033/
- JAMA. Long-term cardiovascular outcomes of GLP-1 receptor agonists. JAMA. https://jamanetwork.com/journals/jama/fullarticle/2810542
- FDA. FDA’s concerns about unapproved GLP-1 drugs used for weight loss. FDA. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- National Center for Biotechnology Information. GLP-1 receptor agonists and their effects. NCBI. https://pmc.ncbi.nlm.nih.gov/articles/PMC6483112/
- Harvard Health. Side effects of GLP-1 diabetes and weight-loss drugs. Harvard Health. https://www.health.harvard.edu/staying-healthy/glp-1-diabetes-and-weight-loss-drug-side-effects-ozempic-face-and-more
- National Center for Biotechnology Information. Mechanisms of GLP-1 receptor agonists. NCBI. https://www.ncbi.nlm.nih.gov/books/NBK572151/
- University of Chicago Medicine. Research on GLP-1 drugs. UChicago Medicine. https://www.uchicagomedicine.org/forefront/research-and-discoveries-articles/2024/may/research-on-glp-1-drugs
- Pharmacy Times. Five unexpected new uses for GLP-1 receptor agonists. Pharmacy Times. https://www.pharmacytimes.com/view/five-unexpected-new-uses-for-glp-1-receptor-agonists
- Cleveland Clinic. GLP-1 agonists overview. Cleveland Clinic. https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
- UpToDate. Glucagon-like peptide-1-based therapies for type 2 diabetes. UpToDate. https://www.uptodate.com/contents/glucagon-like-peptide-1-based-therapies-for-the-treatment-of-type-2-diabetes-mellitus
- Nature. Innovations in GLP-1 agonist research. Nature. https://www.nature.com/articles/s41392-024-01931-z
- National Center for Biotechnology Information. Efficacy and safety of GLP-1 receptor agonists. NCBI. https://pmc.ncbi.nlm.nih.gov/articles/PMC8346189/
- The Lancet Diabetes & Endocrinology. Advances in GLP-1 receptor agonist therapies. The Lancet. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00271-7/abstract
- National Kidney Foundation. GLP-1 receptor agonists in kidney care. NKF. https://www.kidney.org/kidney-topics/glp-1-receptor-agonists-glp-1-ras
- Cleveland Clinic Journal of Medicine. GLP-1 receptor agonists in clinical practice. CCJM. https://www.ccjm.org/content/89/8/457
- DCAT Value Chain Insights. The battle of the blockbusters: GLP-1 agonists. DCAT VCI. https://www.dcatvci.org/features/the-battle-of-the-blockbusters-glp-1-agonists/
- Sage Journals. GLP-1 agonists: A review of new developments. Sage Journals. https://journals.sagepub.com/doi/10.1177/2042018821997320
- Ozmosi. Market overview of GLP-1 agonists and the obesity market. Ozmosi. https://www.ozmosi.com/market-overview-glp-1-agonists-and-the-obesity-market/
- Mayo Clinic. Understanding GLP-1 receptor agonists for diabetes. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/expert-answers/byetta/faq-20057955
- National Center for Biotechnology Information. GLP-1 receptor agonists: A pharmacological perspective. NCBI. https://pmc.ncbi.nlm.nih.gov/articles/PMC5397288/
- FDA. Ongoing evaluation of suicidal thoughts in patients using GLP-1 agonists. FDA. https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type
- MedCentral. Choosing the right GLP-1 agonist for patients. MedCentral. https://www.medcentral.com/meds/which-glp-1-agonist-if-any-is-right-for-my-patient